K.O.S. (neuromodulation system for the treatment of chronic migraine)

2021: Start using the neuromodulation system to treat chronic migraine

At the end of May 2021, the Swedish medical technology company Chordate Medical developed and patented a new neuromodulation technology for the treatment and prevention of chronic migraine in adult patients. The development was called K.O.S.

The effectiveness and safety of the new system were proven by the results of analysis of data from an ongoing clinical study of patients from Germany and Finland. Based on these data, the system received CE marking, that is, this treatment method meets the requirements of clinical effectiveness and safety of the European Directive on medical devices. CE markings confirm that the technology complies with the current regulations for the release of medical devices MDD 93/42/EEC. Thus, doctors can begin to use K.O.S. technology. in clinical practice.

Chordate Medical Holding AB CEO Anders Weilandt noted that the company will continue to investigate the new method of migraine treatment and prevention according to the plan until the highest results are achieved, but the developers have already completed their main goal of bringing the technology to market.

The aim of the study shifted - future results will be used to support sales and confirm the clinical effect of the new technique through academic publications. Thus, we will take a big strategic step forward, because the results of the study will allow us to establish sales in selected markets in Europe, "he said.

Previously, neuromodulation technology was successfully used to treat chronic nasal congestion and rhinitis in the United States, and was also introduced in selected markets in the EU and Saudi Arabia. Chordate Medical Holding AB also extended the "CE" labeling for the use of neuromodulator devices in chronic rhinitis until May 2024.^[1]

Notes